[Comment] Will mezigdomide find its place in the T-cell redirecting treatment landscape for relapsed multiple myeloma?

Summary

A Lancet commentary discusses mezigdomide's potential role in the evolving treatment landscape for relapsed or refractory multiple myeloma, where T-cell redirecting therapies including anti-BCMA CAR-T cells and bispecific antibodies have demonstrated superiority over standard regimens but face access limitations.